Back

Medulloblastoma Initiative Unveils Latest Impact Report Showcasing Breakthrough FDA-Approved Clinical Trials

The Medulloblastoma Initiative (MBI) is thrilled to share its latest Impact Report, highlighting the approval of two clinical trials by the FDA (Food and Drug Administration). This marks an unprecedented advancement in our research as we continue our mission to find a cure for this devastating disease.

To all our supporters, MBI extends its deepest gratitude. For those who haven’t joined us yet, we invite you to consider supporting our cause.

Together, we can make a significant impact and create a better world.

Read the full report

Share This

Chamber Updates Stay connected with Chamber activities